TON - August 2021 Vol 14, No 4


Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›

Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. In the past 10 years alone, the number of drugs approved by the FDA for non–small-cell lung cancer (NSCLC) has exceeded the previous 10 decades combined. Read More ›

Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States. Read More ›

Page 2 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: